Missling mentioned eventual prophylaxis.
For the Anavex phone conference, I listened closely, trying to discover where my own understandings of Anavex drug biology failed to match what Dr. Missling discussed. Very pleased. Everything he mentioned aligned with my own perceptions and understandings. Seemed that he was reading from notes I would have assembled for such an event (which was also the case with the comments of Dr. Randi Hagerman and her comments on blarcamesine not long ago).
In honesty, I do not follow closely the on-going details of the several Anavex clinical trials, either in progress, or to come. I'm only interested in their final read-outs, and Dr. Missling mentioned that some of those will appear later this year. Well and good.
I would have loved to hear one of the questioners ask if any information on animal studies regarding blarcamesine's suppression of aging and geriatric disease onset have been conducted. Inasmuch as this event was for stock analysts, no such question was posed, But I did note that Dr. Missling, for the first time, I believe, posed a potential prophylactic application of blarcamesine, suggesting that some time in the future the drug might be an "aspirin," taken daily for its health benefits; disease prophylaxis, actual prevention.
I've been contending that for sometime; where blarcamesine's greatest health benefits and impacts are likely with its prophylactic uses, taken, as Missling alluded, to actually prevent the onset of geriatric diseases. Not just to treat Alzheimer's, but to actually prevent it.
Should that happen, ponder the implications, both for citizens' mental health, and for the sales revenues coming to Anavex Life Sciences Corp.
I'll be maintaining my long-term, five-year investment periods perspective regarding AVXL. The first five-year corporate development and start-up period is coming to an end. The next fire-year period will be with ever-increasing sales revenues. The five-year investment period after that will have Anavex Life Sciences Corp at the top of the world's pharmaceuticals, with all that will entail.
